Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

Lofters, W S

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug 1997 - 2966-73 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0732-183X

10.1200/JCO.1997.15.8.2966 doi


Administration, Oral
Antiemetics--adverse effects
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Dexamethasone--administration & dosage
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Indoles--adverse effects
Injections, Intravenous
Male
Middle Aged
Nausea--chemically induced
Ondansetron--adverse effects
Premedication
Quality of Life
Quinolizines--adverse effects
Vomiting--chemically induced